1-6 of 6
Carolyn Owen, MDFRCPC
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Retrospective Review of Treatment Patterns and Outcomes of DLBCL in the Very Elderly: A Single Centre Experience

Farheen Manji, MD, Carolyn Owen, MDFRCPC
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-139654
Published: 2020
Journal Articles

Generalizability of Landmark Clinical Trials in Diffuse Large B Cell Lymphoma to Real-World Patients: A Single-Centre Retrospective Cohort Study

Marta Davidson, MDPhDFRCPC, Alexandra Rice, MD, Douglas A. Stewart, MD FRCPC, Carolyn Owen, MDFRCPC
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137541
Published: 2020
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

Anuja Chatterjee, MSc, Gijs Van de Wetering, PhD, Ron Goeree, Anne Marie Desbois, Patricia Manzi, MSc, BPharm, Beenish S Manzoor, PhD, Carolyn Owen, MDFRCPC, Kavita Sail, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-134596
Published: 2020
Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Matthew C. Cheung, MDMSc, Nicole Mittmann, PhD, Carolyn Owen, MDFRCPC, Nizar Abdel-Samad, MD, Graeme Fraser, Selay Lam, MDBSc,FRCPC, Michael Crump, MD, Catherine Sperlich, Richard van der Jagt, Stephen Couban, MDBSc, Jennifer A. Woyach, MD, Amy S. Ruppert, PhD, Allison M Booth, Sumithra J Mandrekar, PhD, Gail T. McDonald, Lois E. Shepherd, Anca Prica, MD, Hope Yen, Bingshu E. Chen, Annette E. Hay
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–30.
https://doi.org/10.1182/blood-2020-136692
Published: 2020
Journal Articles

Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Rosemary Anne Harrup, Carolyn Owen, MDFRCPC, James D'Rozario, Tadeusz Robak, MDPhD, Arnon P. Kater, Marco Montillo, Javier de la Serna, Marek Trněný, MD, Su Young Kim, Edward Bataillard, Marcus Lefebure, Michelle Boyer, John F. Seymour
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-137415
Published: 2020
Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Arnon P. Kater, MDPhD, Thomas J. Kipps, MD PhD, Barbara Eichhorst, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, James D'Rozario, Carolyn Owen, MDFRCPC, Sarit E Assouline, MD MSc, Nicole Lamanna, MD, Tadeusz J. Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, MD PhD, Marco Montillo, Clemens Mellink, Brenda J. Chyla, Cameron Wilson, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, John F. Seymour
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–21.
https://doi.org/10.1182/blood-2020-136109
Published: 2020